CTXR
Citius Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$0.75
+0.04 (+6.00%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.36M | 3.56M | 3.14M |
| Net Income | 635.6K | 690.8K | 743.5K |
| EPS | — | — | — |
| Profit Margin | 18.9% | 19.4% | 23.7% |
| Rev Growth | -2.5% | +1.7% | -0.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 7.22M | 7.38M | 6.82M |
| Total Equity | 4.98M | 5.33M | 5.32M |
| D/E Ratio | 1.45 | 1.39 | 1.28 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.24M | 1.20M | 1.26M |
| Free Cash Flow | 627.5K | 529.6K | 500.9K |